AntriaBio

AntriaBio

AntriaBio

AntriaBio is developing proprietary products in sustained release injectable formulations including AB101, a once-a-week basal insulin. $ANTB
Type
B2b
Founded
2010
Raised
$44.4M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$13,000,000
Post-IPO equity - 2017
Medici Investment Ildong Pharmaceutical Aju Pharma
$6,700,000
Post-IPO equity - 2017
Team Size
10+
Employees
$13,000,000 Post-IPO equity
BizWest

Pharmaceutical firm in Louisville raises $13 million

$6,700,000 Post-IPO equity
BizWest

AntriaBio raises $6.7M, plans to file new drug application

$7,000,000 Venture capital
Xconomy

Colorado Roundup: AntriaBio Raises $7M, VSCO Buys Artifact Uprising